Overview

Transform Oncology Care with Precision AI

Personalized cancer treatment recommendations to optimize outcomes, reduce toxicity, and empower your oncology teams.

Overview

Cancer therapy is complex, multifaceted, and highly personalized—every patient's genetic makeup can influence drug efficacy and risk of severe adverse events. PGxAI's Oncology module (PGxAstraea™) merges cutting-edge pharmacogenomics with real-world clinical data to help oncologists and health systems make informed decisions at every step of cancer treatment.

•

70+ oncology drugs covered, including chemotherapy, targeted therapies, immunomodulators, and hormonal agents.

•

46 critical genetic markers integrated for nuanced, patient-specific insights.

•

Generative AI that refines treatment recommendations in real time, reducing adverse reactions and improving survival rates.

Key Highlights

Serving every stakeholder in healthcare

Schedule a Demo Contact Us

Comprehensive Drug-Gene Database

From platinum-based regimens (Cisplatin, Carboplatin) to targeted therapies (Erlotinib, Nilotinib), PGxAI provides actionable insights across a wide range of oncology treatments.

Real-World Evidence & Machine Learning

Our platform continuously learns from clinical outcomes across multiple facilities, ensuring the most up-to-date evidence for your oncology team.

Minimized Toxicity, Optimized Efficacy

Predictive analytics help clinicians tailor dosages, avoid harmful drug interactions, and select the most effective regimens for each patient's genetic profile.

Scalable for Health Systems

Designed for quick adoption across multiple sites, PGxAI fits seamlessly into existing oncology workflows, from small clinics to expansive hospital networks.

Reimbursable Testing & Analysis

Our pharmacogenomic tests align with recognized CPT codes, simplifying billing and improving the cost-effectiveness of personalized cancer care.

Clinical Impact

Maximize Clinical Impact with PGxAI

Schedule a Demo Contact Us

Precision-Guided Therapy Optimization

PGxAI mines genotype, phenotype, and comorbidity data in real time to recommend the optimal drug–dose pair at the first prescription. By accounting for actionable allelic variants and metabolic phenotypes, it minimizes trial-and-error titration and sharply reduces severe drug–gene and drug–drug interactions.

Superior Patient Outcomes & Experience

Genomically informed prescribing lowers adverse-event rates, accelerates therapeutic response, optimizes co-administered medications and boosts adherence. Patients spend less time managing side effects and more time benefiting from treatment, enhancing both clinical endpoints and satisfaction metrics across specialties.

Demonstrable Value-Based Performance

Fewer complications, shorter lengths of stay, and reduced readmissions translate into measurable gains on CMS and private-payer quality dashboards. Institutions leveraging PGxAI can document higher quality scores and capture value-based reimbursement upside while lowering total cost of care.

Seamless Team Integration & Scalability

The platform embeds directly into leading EHRs and e-prescribing systems, delivering concise, guideline-aligned reports that support rapid decision-making for multidisciplinary teams. Standardized APIs and CDS hooks allow effortless expansion from pilot units to enterprise-wide deployment without workflow disruption.

Drug Categories

PGxAI supports a broad spectrum of oncology treatments

Schedule a Demo Contact Us

Chemotherapy Agents:

Doxorubicin, Fluorouracil, Cyclophosphamide, etc.

Targeted Therapies:

Gefitinib, Nilotinib, Erdafitinib.

Hormonal Therapies:

Tamoxifen, Anastrozole, Exemestane.

Platinum-Based Regimens:

Cisplatin, Carboplatin, Oxaliplatin.

Immunomodulators & Epigenetic Drugs:

Sacituzumab Govitecan, Belinostat, Irinotecan. Each recommendation is backed by a robust AI engine that considers genetic variants, molecular data, and published clinical evidence.

Case Study

Midtown Oncology Center

Schedule a Demo Contact Us

Challenge

High rates of toxic side effects in metastatic breast cancer patients on combination chemotherapy, leading to repeated ED visits.

Solution

PGxAI deployed to analyze each patient's genetic markers and identify optimal dosing regimens.

Results

28% drop in treatment-related hospital admissions over 6 months, improved patient satisfaction scores, and streamlined pharmacy management.

What's next

Ready to Shape the Future of Precision Medicine?

Empower your oncology department with a platform that maximizes patient outcomes and minimizes complications. Experience how precision genomics can transform cancer care across your health system.

Request a Demo

Schedule a personalized walkthrough of PGxAI's Oncology module.